Biomedical subjects

J Olofsson

Publications and source records attributed to J Olofsson.

165 records · Page 10Linked to original sources

PubMedDate not supplied

Expression of epidermal growth factor receptor in laryngeal dysplasia and carcinoma.

The immunoreactivity of epidermal growth factor receptor (EGFR) was studied in laryngeal biopsy specimens from 24 patients. The study comprised 5 cases of normal laryngeal mucosa, 5 cases of dysplasia, 7 cases of well differentiated squamous cell carcinoma, and 7 cases of poorly to moderately differentiated squamous cell carcinoma. EGFR was in general not expressed in normal and dysplastic epithelia, whilst all carcinomas showed a rather strong positive immunoreactivity. There was no significant difference in staining patterns between the well and poorly to moderately differentiated carcinomas. The results suggest that EGFR constitutes a component of neoplastic, but probably not preneoplastic, laryngeal disease. The study failed to reveal any difference in staining pattern between different types of laryngeal squamous cell carcinoma.

Antibodies, Monoclonal↗

PubMedDate not supplied

Bronchomotor tone and the slope of phase III of the N2-test.

To determine the influence of bronchomotor tone on the slope of phase III of the N2-test, we studied subjects with reversible airflow limitation, who inhaled a standard dose of salbutamol. The design of the study allowed separation and comparison of the effects on the slope of phase III of changes in bronchomotor tone and in preinspiratory volume. The study shows that in subjects with a substantial reversibility of airflow limitation changes in the slope of phase III induced by salbutamol are related more to a change in preinspiratory volume than to a change in bronchomotor tone per se.

Adult↗

PubMedDate not supplied

Effect of increasing bronchodilatation on the single breath nitrogen test.

To determine if and how changes of the slope of phase III of the N2 test reflect drug-induced bronchodilatation, we studied patients with moderate to severe reversible airflow limitation who inhaled increasing doses of salbutamol. The bronchodilating response on each dose level was monitored both by the N2 test and dynamic spirometry. The study shows that the slope of phase III is related to drug-induced bronchodilatation in a dose-dependent way. Furthermore, the decrease of the slope of phase III mirrors the concomitant increase of FEV1. These results are consistent with bronchomotor tone as a determinant of the slope of phase III. Alternatively, the decrease of the slope of phase III may be independent of bronchomotor tonus per se and be explained by a decrease in residual volume as reflected by the observed dose-dependent increase in vital capacity.

Aged↗